Investment Thesis
Kyverna is a pre-revenue biotech company with accelerating cash burn (-$41.6M annually) and only ~9 months of runway at current burn rate. While the balance sheet appears strong, negative trends in profitability (losses worsening YoY) and lack of revenue-generating products create unsustainable economics requiring dilutive capital raises.
Strengths
- Strong balance sheet with $257M total assets and $195.6M stockholders' equity
- Excellent liquidity position (8.15x current ratio) to fund near-term operations
- Zero debt burden eliminates refinancing and interest coverage risk
Risks
- Pre-revenue stage with no commercial products generating revenue
- Unsustainable cash burn of -$41.6M annually against only $32.2M cash reserves (~9 months runway)
- Deteriorating financial performance with losses worsening YoY (-26.5% net income decline)
- Will require dilutive capital raises to extend runway and fund development
- Biotech execution risk with no visibility into clinical trial success or commercialization timeline
Key Metrics to Watch
- Monthly cash burn rate and time to next funding event
- Clinical program advancement and regulatory milestone achievements
- Cash position trajectory and any announced capital raises or partnership deals
Financial Metrics
Revenue
N/A
Net Income
-39.7M
EPS (Diluted)
$-0.66
Free Cash Flow
-41.6M
Total Assets
257.0M
Cash
32.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-20.3%
ROA
-15.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.15x
Quick Ratio
8.15x
Debt/Equity
0.00x
Debt/Assets
23.9%
Interest Coverage
-498.40x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:43:11.100864 |
Data as of: 2026-03-31 |
Powered by Claude AI